Rapt Therapeutics Inc.

11/11/2024 | Press release | Distributed by Public on 11/11/2024 07:17

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury